Clinical Trials Sponsored by Mazonson & Santas Inc.

Total 205 results

Mazonson & Santas Inc.

Completed

ADHOC Mindfulness-Based Research (AMBR)

Depression | Anxiety | Hiv | Loneliness

United States
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
Santen Inc.

Completed

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program (SPRING)

Non-Infectious Uveitis of the Posterior Segment of the Eye

United States, France, Turkey, Italy, Austria, India
Santen Inc.

Completed

Study Assessing Double-masked Uveitis Treatment (SAKURA)

Uveitis; Posterior, Disorder

United States, France, Italy, Poland, United Kingdom, Germany, Spain, Austria, Colombia, Israel, India, Turkey, Japan, Peru, Argentina, Brazil, Chile
Santen Inc.

Completed

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (VAPOR1)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Santen Inc.

Completed

DE-117 Spectrum 5 Study

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (ANGEL-2)

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SEE-1)

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma or Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen Inc.

Completed

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Healthy

United States
Santen Inc.

Terminated

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Non Infectious Uveitis

United States, India, Italy, Argentina
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Santen Inc.

Completed

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Santen Inc.

Completed

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen Inc.
MacuSight, Inc.

Completed

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Diabetic Macular Edema

United States
Santen Inc.
MacuSight, Inc.

Completed

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Diabetic Retinopathy | Diabetic Macular Edema

United States
Santen Inc.
MacuSight, Inc.

Completed

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Dry Eye

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
ActualEyes Inc.

Recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States
Santen Inc.
Vistakon Pharmaceuticals

Terminated

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

Corneal Transplantation

United States
Stanford University
Santen Inc.

Withdrawn

Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)

Panuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis

United States
Santen Inc.
Vistakon Pharmaceuticals

Completed

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

Cataract

United States
Santalis Pharmaceuticals, Inc.
ClinDatrix, Inc.; Fremantle Dermatology

Withdrawn

A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Atopic Dermatitis
Santalis Pharmaceuticals, Inc.
ClinDatrix, Inc.; Fremantle Dermatology

Withdrawn

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in Adults

Plaque Psoriasis

Australia
The Cleveland Clinic
Santen Inc.

Active, not recruiting

Imaging Quantification of Inflammation (IQI) (IQI)

Uveitis

United States
University of California, Santa Barbara
Rendever, Inc.

Completed

Technology and Family Thriving Study (Thrive)

Quality of Life | Dementia | Alzheimer Disease | Mental Health Wellness 1 | Loneliness | Caregiver Burnout | Family Relationship

United States
Cipherome, Inc.
Santa Clara Valley Medical Center

Completed

DOAC ADRs Retrospective Study on Genetic Variations (DARES1)

Drug-Related Side Effects and Adverse Reactions | Treatment Failure

United States
Cipherome, Inc.
Santa Clara Valley Medical Center

Completed

Association Between Genetic Variant Scores and Warfarin Effect (AWARE1)

Atrial Fibrillation | Deep Vein Thrombosis | Pulmonary Embolism | Intracardiac Thrombus | Venous Thromboembolic Disease

United States
Cipherome, Inc.
Santa Clara Valley Medical Center

Terminated

DOAC ADRs Retrospective Study

Drug-Related Side Effects and Adverse Reactions

United States
Amalgam Rx, Inc.
Kansas City Area Life Sciences Institute, Inc.; University of Kansas; LifeScan

Unknown

mHealth Titration and Management

Diabetes Mellitus, Type 2 | Diabetic Complication

United States
Kansas State University
MGP Ingredients, Inc.

Withdrawn

Long-term Consumption of Resistant Starch Type-4 (RS4)

Overweight or Obesity | Cholesterol, Elevated

United States
University of Kansas
Dairy Management Inc.

Completed

Whey Protein, Resistance Training, and Changes in Body Composition

Obesity

United States
University of Kansas
Dairy Management Inc.

Completed

Substrate Oxidation in Children in Response to High and Low Dairy Intake

Childhood Obesity

United States
Kansas State University
MGP Ingredients, Inc.

Completed

Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes

Hyperglycemia

United States
Kansas State University
MGP Ingredients, Inc.

Completed

Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults

Hyperglycemia

United States
Kansas State University
MGP Ingredients, Inc.

Completed

Resistant Starch on Glycemic Response in Older Adults

Hyperglycemia

United States
Alessandro Santin
ImmunoGen, Inc.

Recruiting

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Endometrial Cancer

United States
Retina Associates, Kansas City
Genentech, Inc.

Unknown

Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Proliferative Diabetic Retinopathy

United States

3

Subscribe